

# Derivation of Trop2-Targeting Antibody-Cytokine Fusion Protein (anti-TROP2 ACFP) for Maximizing Anticancer Effects and Minimizing Side Effects

ABION. INC.



ONCOLOGY	Lead
Product Type	Antibody
Indication	TROP2-positive solid cancers, Antibody-drug conjugates refractory/resistant patients
Target	TROP2, Type I Interferon, IFNAR1/2
MoA(Mechanism of Action)	<ul style="list-style-type: none"> <li>• Inhibits tumor cell proliferation directly</li> <li>• Stimulates anti-tumor immune responses</li> <li>• Maintains fc-mediated.effector functions (ADCC, ADCP)</li> </ul>
Competitiveness	<ul style="list-style-type: none"> <li>• High productivity and purity of IFN mutein enabled by glycoengineering</li> <li>• Reduced systemic toxicity by change of Type I IFN receptor binding kinetics</li> <li>• Beyond ADCs : Superior efficacy against ADC resistance models</li> </ul>
Development Stage	Lead
Route of Administration	Intravenous Infusion

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*